Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.

By The RX Index Editorial TeamLast verified: May 28, 2026Sources: DailyMed, The Lancet, JAMA, CMS, KFF — re-checked monthly

Best GLP-1 for Long-Term Maintenance in 2026

What you can actually stay on — without regaining the weight or going broke

Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.

The RX Index is a pricing intelligence and comparison resource for GLP-1 telehealth providers. Some links on this page are affiliate links. We rank options by evidence, current pricing, and how well they fit you — payout only breaks a tie when the evidence is even. This page is educational. It is not medical advice. Do not start, stop, switch, or change a GLP-1 dose without a licensed clinician.

The best GLP-1 for long-term maintenance is the one you can safely stay on for years — not the one with the cheapest first month. For most people comparing FDA-approved options, the short list is small: Zepbound (tirzepatide) has the strongest weekly maintenance evidence, Wegovy (semaglutide) is the most established, and the Wegovy pill or Foundayo (orforglipron) are the FDA-approved pills if you’d rather skip needles. Picking a provider comes down to one question: does insurance matter to you, or are you paying cash?

Match the path to your biggest worry

If your priority is…	Best starting point	Why
Strongest weekly maintenance evidence	Zepbound	Best dedicated maintenance data; real maintenance price runs higher than the starter price
Established semaglutide, weekly	Wegovy pen	Longest track record and a clear FDA-labeled maintenance dose
An FDA-approved pill	Wegovy pill or Foundayo	Wegovy pill has strict timing rules; Foundayo is easier to take but newer
Help with insurance or prior authorization	Ro	Free coverage check first; handles the paperwork once you’re approved
Cash-pay brand-name, your choice of doctor	Sesame	Shows cash prices and lets you pick your provider
The lowest predictable monthly price	A compounded program to vet	Cheaper, but not FDA-approved — verify the pharmacy and source first

Have insurance? Check coverage free with Ro →Paying cash? Compare brand prices on Sesame →Not sure yet? 60-sec quiz →

What is the best GLP-1 for long-term maintenance?

The best GLP-1 for long-term maintenance depends on your biggest failure point: regain, cost, coverage, side effects, needles, or supply. For most people weighing FDA-approved options, Zepbound is the strongest weekly evidence pick, Wegovy is the established semaglutide default, and the Wegovy pill or Foundayo are the FDA-approved pills. Ro is the best route if insurance matters; Sesame is the cleaner cash-pay brand-name route.

Maintenance is a different question than “what lost me the weight.” Losing weight is a sprint. Keeping it off is the long game. The smart move isn’t chasing the lowest intro price — it’s picking the path you can keep paying for, refilling, and tolerating a year or two from now.

Do you have to stay on a GLP-1 forever?

For most people, keeping the weight off means staying on some form of treatment — that’s the honest answer. In a 2026 meta-analysis from the University of Cambridge that pooled 48 studies, people regained about 60% of their lost weight within a year of stopping a GLP-1, with roughly 25% of the original loss tending to stay off. Obesity behaves like a long-term condition. The medicine manages it. It doesn’t cure it.

Here’s the flaw in this whole category, and we’d rather you hear it from us: there is no GLP-1 — brand-name or compounded, pill or shot — that lets most people lose the weight, quit, and keep it off. The biology fights back. When the drug leaves, appetite returns. The trials are blunt about it.

What the research shows about stopping	The finding
STEP 1 extension (semaglutide, 2022)	Regained about two-thirds of lost weight one year after stopping
SURMOUNT-4 analysis (tirzepatide)	About 82% of people who stopped regained more than a quarter of their loss within a year
Cambridge meta-analysis (2026)	About 60% of lost weight regained in a year; roughly 25% of the loss tended to stay off
SURMOUNT-MAINTAIN (tirzepatide, 2026)	Staying on — even at a lower dose — kept far more weight off than stopping

This is exactly why the cheapest first month is the wrong thing to chase. A $99 starter deal means nothing if the plan falls apart at month six. Maintenance is measured in years, so you want the path you can actually keep: a dependable supply, a price you can live with, and a dose you can adjust. Pick for the long haul, and “forever” stops being scary. It becomes a plan.

Take the free maintenance quiz →

Medications to ask about, a real cost range, and your best coverage path \u2014 about 60 seconds.

Can you take a lower (cheaper) maintenance dose?

Sometimes yes — and 2026 finally gave us real proof. In the SURMOUNT-MAINTAIN trial (published in The Lancet, May 2026), people who dropped to a lower 5 mg dose of tirzepatide kept off substantially more weight than people who stopped — though the full dose still held off the most. At the end of the trial: weight was down about 21.9% on the full dose, 16.6% on the 5 mg dose, and 9.9% on placebo. The takeaway isn’t “the lowest dose works the same.” It’s that stepping down beats stopping — and for some people, a lower dose could lower the bill too.

If you step down to a lower maintenance dose…	Could your bill drop?	Why
Zepbound	Yes, possibly	Cash price is tiered by dose
Foundayo	Yes, possibly	Cash price is tiered by dose
Wegovy pill	Yes, possibly	Lower doses ($149) cost less than higher ones ($299)
Wegovy pen	Usually not	Cash price is mostly flat (~$349) across 0.25–2.4 mg
Flat-price compounded	No	Same price at every dose (confirm at checkout)

One caution: this is strongest for tirzepatide, and not everyone can step down. KFF Health News notes that many people actually need to stay at a higher dose to hold their weight. Treat dose changes as a conversation with your prescriber — not a DIY money hack.

Which GLP-1 has the strongest evidence for keeping weight off?

The clearest pattern in the research is simple: people who keep taking an effective dose keep the weight off, and people who stop tend to regain. Among FDA-approved options, Zepbound has the strongest weekly maintenance case, Wegovy is the most proven semaglutide, and the Wegovy pill and Foundayo are the FDA-approved daily pills. All four have a clear, labeled maintenance dose — something compounded versions don’t have.

Zepbound (tirzepatide) — the strongest weekly option for many people

Zepbound’s maintenance dose for weight management is 5 mg, 10 mg, or 15 mg once a week. The 2.5 mg dose is only for starting out — it is not a maintenance dose. Tirzepatide also has the most direct “what happens when you stop” data, and it’s sobering: stopping leads to substantial regain (SURMOUNT-4).

One honest catch: the cheap headline price you see for Zepbound is usually the starter dose. Cash pricing starts at $299/month for the first month, but your maintenance dose will cost more — more on the real numbers in the cost section below.

Wegovy (semaglutide injection) — the established default

Wegovy’s maintenance dose is 2.4 mg once a week (with 1.7 mg as a fallback if 2.4 mg is hard to tolerate). Semaglutide has years of real-world use behind it. There’s also a newer, stronger version — Wegovy HD (7.2 mg) — that became available nationwide in April 2026. It’s meant for people who have tolerated 2.4 mg for at least four weeks and need additional weight reduction; in its trial, average weight loss was about 21% at 72 weeks for people who stayed on treatment.

Wegovy pill (oral semaglutide) — FDA-approved, needle-free

The Wegovy pill’s recommended adult maintenance dose is 25 mg once a day. It works, but it’s fussy to take: empty stomach, plain water only, and you wait before eating, drinking, or taking other pills. If you’re disciplined about timing, it’s a solid needle-free option. If you’re not, that daily routine can trip you up.

Foundayo (orforglipron) — the easy-to-take new pill

Foundayo is a once-daily pill you can take any time of day, with or without food, no water rules — much simpler than the Wegovy pill. You start at 0.8 mg and step up every 30+ days; from 5.5 mg your clinician may move you up to 17.2 mg based on how you respond. In its phase 3 ATTAIN-1 trial, the highest dose led to about 11% average weight loss at 72 weeks. The honest trade-off: it’s the newest of the four, so it has the least long-term maintenance data.

Medication	How you take it	Maintenance dose (FDA label)	Best maintenance fit
Zepbound (tirzepatide)	Weekly shot	5, 10, or 15 mg/week	Strongest weekly evidence; you’re okay with injections
Wegovy (semaglutide)	Weekly shot	1.7 or 2.4 mg/week (7.2 mg HD for those who tolerated 2.4 mg and need more)	Most established; want a proven track record
Wegovy pill (semaglutide)	Daily pill	25 mg/day	Needle-free and you’ll follow strict timing rules
Foundayo (orforglipron)	Daily pill	Steps up to 5.5–17.2 mg/day	Needle-free and want the easiest pill to take

Check my coverage for Zepbound or Foundayo →

Zepbound vs. Wegovy for maintenance: which one wins?

Zepbound is the better fit when maximum weekly evidence and higher weight-loss potential matter most; Wegovy is the better fit when you want the longer semaglutide track record or your insurance covers it more reliably. Both have FDA-labeled maintenance doses and direct evidence that staying on them beats stopping. The real winner is the one you can tolerate, refill, and afford at the dose your clinician wants you on.

Go Zepbound if…

You want the strongest dedicated maintenance data, you tolerate injections, and you’ve found cost works at your dose.

Go Wegovy if…

You prefer the longest semaglutide track record, want a pill option in the same drug family (the Wegovy pill), or your plan covers Wegovy more reliably.

Either way…

Coverage can decide it for you. If your insurance covers one and not the other, that’s often your answer — which is why a free coverage check is the fastest shortcut.

How much does long-term GLP-1 maintenance really cost in 2026?

The real cost isn’t the first-month price. It’s what you’ll pay at the dose you settle on, month after month, for years. In 2026, FDA-approved pills can start around $149/month at lower doses, while weekly brand-name shots commonly run about $349–$449/month on telehealth platforms — and as high as roughly $699/month for some doses bought direct from the manufacturer. Compounded programs run lower — often $199–$399/month — but those medicines aren’t FDA-approved.

Path	Published cash price	The maintenance catch
Wegovy pen (NovoCare / Ro)	$199/mo first month, then $349/mo (up to 2.4 mg); $399/mo for Wegovy HD 7.2 mg	The $199 is a starter promo (through June 30, 2026) — your maintenance price is $349–$399
Wegovy pill (NovoCare / Ro)	$149/mo for lower doses; $299/mo for higher doses	25 mg is the maintenance dose, so plan for ~$299/mo
Zepbound KwikPen (Ro / Lilly)	$299/mo the first month, then $399–$449/mo on Ro; some doses run up to ~$699/mo direct	2.5 mg is the starter; 5, 10, and 15 mg are the labeled maintenance doses
Foundayo (Ro / LillyDirect)	$149/mo the first month, then $199–$299/mo (up to ~$349/mo for the highest doses without the refill offer)	Maintenance is usually 5.5 mg+, so plan for ~$299–$349/mo
Ro Body membership (sponsored affiliate link, opens in a new tab)	$39 first month, then $149/mo (as low as $74/mo on an annual plan)	This is the program fee — medication is billed separately
Sesame program	Provider care from $99/mo (as low as $59/mo on an annual plan)	Total = subscription + medication, billed separately
Compounded (Eden, Yucca, others)	Often $199–$399/mo, flat at every dose	Lower cost, but the medicine is not FDA-approved (see the durability section)
Medicare GLP-1 Bridge	$50/mo flat copay, starting July 1, 2026	Pilot program; covers Wegovy, the Zepbound KwikPen & Foundayo; ends Dec 31, 2027

Don’t pick a GLP-1 by its starter price. The cheapest first month is almost always a low starting dose — not the dose you’ll stay on. A “$299 Zepbound” or “$149 Wegovy pill” headline can quietly become $449 or $299 once you’re at your maintenance dose. Always compare the maintenance price.

One more rule that saves real money: if you have insurance, your coverage matters more than the list price. Many plans cover brand-name GLP-1s, sometimes for a copay as low as $25 with a savings program — but most require prior authorization (your doctor has to get the insurer’s okay first, which can take up to 10 business days). That’s why insured readers should check coverage before picking a medication.

Check what my plan covers (free) →Compare cash prices on Sesame →

More detail: GLP-1 cost without insurance — full cash-pay breakdown → · Medicare GLP-1 Bridge $50 copay guide →

Will your medication still be around in a year?

FDA-approved brand drugs (Wegovy, Zepbound, Foundayo) have a clearer regulatory standing and manufacturer-backed supply. Compounded semaglutide and tirzepatide are still available — but on shakier legal ground heading into 2027. For a choice you want to count on for years, supply matters as much as price.

Compounded:A drug mixed by a pharmacy rather than made by the original manufacturer. Compounded GLP-1s are not FDA-approved — the FDA does not review them for safety, quality, or how well they work.

503A pharmacies:Regular compounding pharmacies that mix a drug for one patient at a time.

503B pharmacies:Larger “outsourcing facilities” that can make bigger batches.

Here’s the timeline that matters. During the 2022–2024 shortage, pharmacies were allowed to compound GLP-1s at scale. Then the shortages ended — tirzepatide in late 2024 and semaglutide in February 2025 — which removed the main legal reason for large-scale compounding. Then, on April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide from the 503B list entirely, saying there’s no clinical need to compound them when FDA-approved versions are on the shelf. The public comment window runs through June 29, 2026. Patient-specific (503A) compounding continues for now, but the direction is clearly toward fewer compounded options, not more.

The honest trade-off

Compounded programs are cheaper. But the medicine isn’t FDA-approved, and the rules are tightening. If a more dependable, clearly regulated path for the next three to five years is your top priority, an FDA-approved brand through Ro is the safer bet — its availability doesn’t depend on these compounding rules. If saving money each month matters more and you understand the regulatory risk, a compounded program can still make sense. No drug supply is ever guaranteed — but one of these paths is far less exposed to a rule change.

See FDA-approved options with Ro →

Which provider is best for long-term GLP-1 maintenance?

For FDA-approved maintenance, Ro is the best starting point when insurance or prior authorization matters, and Sesame is best for cash-pay brand-name shopping with your choice of doctor. Compounded programs cost less and fit some cash-pay readers — but verify the medication source, your state, and the ongoing price, and know the regulatory backdrop.

Provider	Best for	Why it works for maintenance	Honest catch
Ro (sponsored affiliate link, opens in a new tab)	Insurance, prior auth, FDA-approved brand	Carries Zepbound & Foundayo (plus Wegovy); free coverage check; insurance team handles prior-auth paperwork; medication priced same as LillyDirect/NovoCare	Membership fee is separate from medication cost
Sesame (sponsored affiliate link, opens in a new tab)	Cash-pay brand-name shoppers	Broad FDA-approved menu (Wegovy, Zepbound, Foundayo); you pick your own doctor; Costco-member pricing available	Provider prices vary; medication isn’t included in the subscription
Eden	Predictable flat-rate cash cost	Flat compounded pricing (same price as dose changes); no membership fee; HSA/FSA and pay-over-time options	Compounded — not FDA-approved; verify current price and pharmacy/source
MEDVi	A compounded option to vet, not a top pick	Compounded shots and daily pills; broad state coverage; free dietitian visits; large patient base	In February 2026 the FDA sent MEDVi a warning letter over false or misleading marketing of its compounded GLP-1s (one of 30 telehealth companies warned). Verify pricing, pharmacy/source, refund terms, and whether cited claims were fixed before choosing
Yucca Health (sponsored affiliate link, opens in a new tab)	A lower-cost compounded option to vet	Online intake, licensed-provider review, pay-over-time options, low starting price	Compounded — not FDA-approved; verify price, pharmacy/source, and state availability

Provider details verified May 28, 2026. Pricing and policies in this category change often — confirm on each provider’s site before you commit.

Why Ro charges a membership fee — and when it’s worth it

That fee is what pays for Ro’s insurance team — the people who fight to get your brand-name drug covered. For many insured patients, getting Wegovy or Zepbound approved saves far more than the membership ever costs. If you’re paying cash and don’t want the fee, a flat-price compounded program like Eden has none.

Why we’re not crowning the cheapest compounded program “best overall”

Long-term maintenance is exactly where FDA approval, a labeled dose, and dependable supply matter most. If your only goal is the lowest possible monthly price, a compounded route may look better on a spreadsheet. Just go in clear-eyed: it’s a different decision than choosing FDA-approved Wegovy, Zepbound, the Wegovy pill, or Foundayo — not a cheaper version of the same thing.

Insurance or brand-name: check coverage with Ro →Cash-pay brand, pick your doctor: Sesame →

Already on a compounded GLP-1? Here’s your move

Don’t stop, switch, or stretch your doses on your own. If you’re already on compounded semaglutide or tirzepatide, the smart next step is to confirm your pharmacy and source, write down your current dose and how you’re responding, ask your clinician about FDA-approved options, and compare the true cost of staying put versus switching.

Quick checklist before you change anything:

1Which pharmacy fills your prescription, and is it licensed in your state?
2What exact formulation and dose are you getting, and who actually compounds it?
3What’s the real price at your maintenance dose — not the intro price?
4How do you cancel, and what happens if a shipment is delayed?
5Can your provider move you to an FDA-approved brand if you ever need to?

Why the urgency to at least look? Because of that April 30, 2026 FDA proposal to pull semaglutide and tirzepatide off the 503B list. It isn’t final, and 503A compounding continues for now. But the trend is clear, and you don’t want to be caught flat-footed mid-journey.

Compare brand-name maintenance paths with Ro →

What happens if you stop a GLP-1?

Most people regain a good chunk of the weight — but not all of it, and not all at once. The Cambridge meta-analysis found people regain about 60% of their lost weight in the first year after stopping, then the regain slows and plateaus, so roughly 25% of the loss tends to stay off. The smart play is to build a fallback before you reduce or stop, so a change in cost, coverage, or appetite doesn’t catch you off guard.

If you and your clinician decide to step down or stop:

•Ask your clinician what amount of regain should trigger action.
•Watch your weekly weight trend — not a scary single-day number.
•Notice if hunger and cravings are creeping back.
•Lock in your protein and strength-training routine first.
•Line up your insurance or cash-pay backup before your last refill.

Read this part twice: regain isn’t a personal failure. It’s biology doing exactly what biology does. This is a planning problem, not a willpower problem. The people who do best are the ones who expected it and had a plan ready.

How do you keep muscle while on GLP-1 maintenance?

Long-term maintenance should protect more than the number on the scale — it should protect your muscle. When you lose weight, some of it can be muscle, and research suggests lean mass can make up a meaningful share of total weight lost. The fix isn’t fancy: eat enough protein, do resistance training, and check in with your clinician or a dietitian.

Tufts:Long-term GLP-1 success depends on more than the prescription — watch nutrient gaps, muscle and bone loss, cost, and regain.

VCU Health clinicians:Basics most people skip: drink enough water, get enough protein (unless your kidneys say otherwise), mix in cardio and strength work, and weigh yourself weekly.

NEJM trial:Combining exercise with medication kept weight off better than either one alone.

A simple maintenance check-in, every month or two, keeps you honest: weight trend, waist, a strength benchmark you can repeat, your protein target, side effects, and a quick cost-and-refill check so nothing surprises you.

Build my maintenance plan (60-sec quiz) →

Get a personalized checklist built around your situation.

Best GLP-1 for maintenance if you hate needles

If you want an FDA-approved, needle-free option for the long haul, compare the Wegovy pill and Foundayo. Both are daily pills. The difference is how easy they are to live with: the Wegovy pill has strict timing rules, while Foundayo can be taken any time, with or without food. For a maintenance routine you’ll actually stick to, that daily friction is the deciding factor for a lot of people.

Choose the Wegovy pill if…

You want established semaglutide in pill form and you don’t mind the routine: empty stomach, plain water, and a wait before food or other pills. Maintenance dose: 25 mg/day.

Choose Foundayo if…

You want the easiest pill to fit into real life — any time of day, food or no food — and you’re comfortable with a newer medication. Maintenance dose: steps up to 5.5–17.2 mg/day.

Both are FDA-approved with a clear labeled maintenance dose. One thing to keep in perspective: the weekly shots (Wegovy and Zepbound) still have more long-term, real-world data behind them. If maximum proof matters more to you than avoiding needles, a shot may still win.

Check oral GLP-1 options with Ro →

Does the Bridge cover the Wegovy pill? → · CMS BALANCE Model Foundayo →

Insurance, Medicare, and HSA/FSA for maintenance

If you have coverage, don’t choose your medication first — choose your coverage first. The best long-term option is often whichever FDA-approved drug your plan will cover month after month, especially since most plans require prior authorization. A covered drug at a $25 copay beats an uncovered drug at full price every time.

Commercial insurance

Start with a coverage check. Ro’s free GLP-1 insurance checker tells you what your plan covers for drugs like Wegovy and Zepbound and whether prior authorization is needed. Once you start with Ro and you’re approved for treatment, its insurance team handles that paperwork — the fastest way to find your real, long-term price.

Medicare (starting July 1, 2026)

Some eligible Medicare Part D members may get Foundayo, all Wegovy formulations, or the Zepbound KwikPen for a flat $50/month through the Medicare GLP-1 Bridge. (Zepbound single-dose vial and standard pen are not included.) CMS sets three eligibility paths, judged by your BMI and conditions when you started GLP-1 therapy:

•BMI 35 or higher (on its own), or
•BMI 30 or higher with heart failure with preserved ejection fraction, uncontrolled high blood pressure (despite two BP medications), or chronic kidney disease stage 3a or higher, or
•BMI 27 or higher with prediabetes, a prior heart attack, a prior stroke, or symptomatic peripheral artery disease.

Read the fine print: it’s a pilot that ends December 31, 2027, and the $50 copay doesn’t count toward your Part D deductible or your $2,100 out-of-pocket cap.

Full Bridge eligibility guide →·Zepbound KwikPen Bridge guide →·Does the Bridge cover Zepbound vials? →

HSA/FSA

Some programs and pharmacies let you pay with HSA or FSA dollars, which stretches your budget. But whether it’s eligible depends on your specific plan and the expense. Don’t assume — confirm with the provider and your plan administrator before counting on it.

Have insurance? Run Ro's free coverage check →

Who should be extra careful before starting or changing GLP-1 maintenance?

Everyone should involve a clinician, but some people need extra caution — and some shouldn’t take these drugs at all. That includes anyone pregnant or planning a pregnancy, anyone with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2, and people with serious stomach or gut conditions or a history of pancreatitis or gallbladder disease. This isn’t the place to self-manage.

The FDA labels for Wegovy, Zepbound, and Foundayo carry a boxed warning about a thyroid tumor risk seen in animal studies. Other things to talk through with your clinician:

•Severe or lasting stomach side effects (nausea, vomiting, constipation, diarrhea).
•Signs of pancreatitis or gallbladder trouble.
•Low blood sugar risk if you also use insulin or a sulfonylurea.
•Any plans for pregnancy.

If any of the above is you, the right next step is a conversation with your clinician — full stop. Bring your questions, and don’t change anything on your own.

What patients say about the experience

These are real, service-focused reviews from Sesame patients on Trustpilot, an independent review platform. We share them to show what the experience can be like — not as proof of weight-loss results, which vary from person to person. The RX Index may earn a commission if you start care through a provider on this page.

“I needed a refill on a long-term prescription. It was easy, fast, and simple.” — Verified Sesame patient, Trustpilot

“I felt very at ease during my appointment… I did not feel I was being sold anything, just offered choices.” — Verified Sesame patient, Trustpilot

Experiences vary, as they do with any provider — some Sesame reviewers flag the 28-day billing cycle or trouble canceling, so read a provider’s recent reviews before you commit. What matters most for long-term maintenance is the thing a first month can’t show: responsive support and easy refills you’ll still want around in month twelve.

How we chose the best GLP-1s for maintenance

We ranked options on five things, in this order: maintenance evidence, dose clarity, true ongoing cost, supply reliability, and regulatory certainty. We deliberately gave FDA-approved options more weight for long-term maintenance, because a cheap first month doesn’t help if your dose has no label support or your supply disappears.

✅ What we actually verified (May 28, 2026)

•FDA-label maintenance doses for Wegovy, Zepbound, the Wegovy pill, and Foundayo (DailyMed and manufacturers’ dosing pages).
•Current cash-pay pricing from NovoCare (Wegovy), Lilly/LillyDirect (Zepbound, Foundayo), Ro, and Sesame.
•The FDA’s compounding shortage-resolution timeline and its April 30, 2026 proposal on the 503B list.
•The Medicare GLP-1 Bridge start date, covered drugs, eligibility tiers, and $50 copay (CMS).
•FDA warning letters issued to 30 telehealth companies (including MEDVi) in February 2026 over compounded-GLP-1 marketing claims.
•Weight-regain evidence (Cambridge/eClinicalMedicine 2026; STEP 1 extension; SURMOUNT-4; SURMOUNT-MAINTAIN).

Recheck before relying on it: provider checkout screenshots, exact state availability, and pharmacy/source disclosures for each compounded provider. Prices in this category change often — we re-verify monthly.

We also have a hard rule: no fake reviews, no star ratings we can’t back up, and we never describe compounded medicine as “the same” as an FDA-approved drug, because it isn’t.

Last verified: May 28, 2026. Re-checked monthly and immediately if CMS changes Bridge rules, FDA updates the 503B list, or provider pricing changes.

Frequently asked questions

What is the best GLP-1 maintenance dose?

There is no single best maintenance dose — it depends on the drug and the person. Wegovy injection maintenance is 1.7 or 2.4 mg weekly, the Wegovy pill is 25 mg daily, Zepbound is 5, 10, or 15 mg weekly, and Foundayo steps up to a range of 5.5 to 17.2 mg daily. Any dose change should be guided by a clinician.

Is Zepbound or Wegovy better for maintenance?

Both are strong. Zepbound (tirzepatide) has the most direct maintenance evidence and tends to produce more weight loss, while Wegovy (semaglutide) has the longest track record and more options, including FDA-approved pills. For maintenance, the tiebreakers are usually tolerability, your cost at your dose, and whether your plan covers it.

Can you take a lower dose of Zepbound for maintenance?

Possibly. In the SURMOUNT-MAINTAIN trial published in The Lancet in May 2026, a reduced 5 mg dose of tirzepatide kept off substantially more weight than stopping, though the full dose maintained the most. Some people need a higher dose, so this should be decided with a prescriber.

How much weight do you regain if you stop a GLP-1?

On average, about 60% of the weight lost is regained within a year of stopping, according to a 2026 University of Cambridge meta-analysis. The regain then slows and plateaus, so roughly 25% of the loss tends to stay off. Results vary by person.

Is compounded semaglutide okay for long-term maintenance?

It can be appropriate for some people under a clinician’s care, but compounded GLP-1s are not FDA-approved, and the FDA does not verify their safety, quality, or effectiveness. With the rules tightening in 2026, supply is less certain than FDA-approved brands, so weigh the lower cost against that risk and verify the pharmacy and source.

Does insurance cover GLP-1s for maintenance?

Sometimes, depending on your plan, and most plans require prior authorization. Because coverage changes your real cost more than anything else, insured patients should check coverage before choosing a medication. A free coverage check is the fastest way to find out.

Can you use HSA or FSA money for GLP-1 maintenance?

Often, but not always. Eligibility depends on your specific plan and the type of expense. Confirm with both the provider and your plan administrator before relying on it.

What should I do if my GLP-1 cost suddenly jumps?

Do not stop cold just because the price changed. Recheck your insurance coverage, compare current cash-pay brand prices, ask your clinician about a dose or medication change, and review your options before your next refill — stopping without a maintenance plan can raise your regain risk.

Still deciding? Let’s make it simple.

You already know the truth most pages won’t tell you: keeping the weight off usually means staying on some form of treatment. The smartest move is choosing the path you can actually keep. If insurance matters, start with a free coverage check. If you’re paying cash, compare brand prices. And if you want it mapped out for your situation in about a minute:

Take the free 60-second GLP-1 maintenance quiz →

Related guides

Sources

Budini B, Luo S, et al. Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine (The Lancet Discovery Science), 2026. DOI: 10.1016/j.eclinm.2026.103796.
Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4). JAMA, 2024 (PubMed 38078870); SURMOUNT-4 regain analysis, American College of Cardiology, 2025.
SURMOUNT-MAINTAIN: Tirzepatide for maintenance of bodyweight reduction. The Lancet, May 12, 2026 (DOI: 10.1016/S0140-6736(26)00656-2). Week-112 results: −21.9% MTD, −16.6% with 5 mg, −9.9% placebo.
DailyMed (FDA labels): Wegovy (injection and tablets), Zepbound, Foundayo.
Foundayo dosing — Lilly HCP dosing page and medical.lilly.com; ATTAIN-1 results via Eli Lilly.
Wegovy cash-pay pricing — NovoCare (novocare.com) and Wegovy.com; Wegovy HD launch (Novo Nordisk, April 7, 2026).
Zepbound and Foundayo cash-pay pricing — Ro (ro.co/weight-loss/pricing); zepbound.lilly.com; lilly.com/lillydirect.
Ro pricing, free GLP-1 insurance checker, and insurance concierge — ro.co/weight-loss.
Sesame pricing and program — sesamecare.com; Sesame blog.
FDA compounding policy — shortage-resolution timeline and April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list.
FDA warning letters — 30 telehealth companies warned over compounded-GLP-1 marketing (FDA news release, March 3, 2026); MEDVi, LLC warning letter (MARCS-CMS 721455, February 20, 2026).
Medicare GLP-1 Bridge — CMS program page; KFF Health News and NPR (May 2026): eligibility tiers and copay details.
KFF polling on GLP-1 affordability — KFF Health News / NPR (May 2026).
Long-term GLP-1 and lifestyle — Tufts Now (2025); VCU Health; NEJM exercise + liraglutide maintenance trial (NEJMoa2028198).

By The RX Index Editorial Team. Published May 28, 2026. Last verified: May 28, 2026. Medical disclaimer: This article is for education only and is not a substitute for professional medical advice. GLP-1 medications are prescription drugs that require evaluation by a licensed clinician. Do not start, stop, switch, or change your dose without talking to your prescriber. Compounded medications are not FDA-approved; the FDA does not review them for safety, effectiveness, or quality. Some links are affiliate links — we may earn a commission at no extra cost to you.